Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.43Last Year’s EPS
-1.7Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -35.51%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including the start of a pivotal Phase 3 trial, regulatory approvals, and promising preliminary data. However, financial constraints and potential regulatory hurdles in the EU were noted as significant challenges.Company Guidance
During the Moleculin Biotech First Quarter 2025 Update Conference Call, guidance was provided on several key metrics and milestones. The Phase 3 MIRACLE trial for Annamycin, aimed at treating relapsed and refractory acute myeloid leukemia (AML), has officially commenced with the first patient treated and 38 sites selected worldwide. The European Medicines Agency approved the trial in nine EU countries, marking significant progress. Moleculin also received a new generic drug name, naxtarubicin, for Annamycin. The company plans to release final data from the MB-107 trial on advanced soft tissue sarcoma soon. Financially, Moleculin ended the quarter with $8 million in cash, projecting the need to raise $15 million to extend operations into the first quarter of 2026. This funding is expected to support the initial 45-subject data readout, moving towards a second data readout in the first half of 2026. The company is focused on increasing its market cap, with Annamycin positioned as a potentially groundbreaking non-cardiotoxic anthracycline.Start of Phase 3 MIRACLE Trial
The Phase 3 MIRACLE trial for Annamycin in treating relapsed and refractory acute myeloid leukemia has officially started with 38 sites selected worldwide.
European Medicines Agency Approval
The company received complete sign-off from the European Medicines Agency to open the trial in nine countries in the EU, marking a major milestone in regulatory approval.
New Generic Drug Name for Annamycin
The World Health Organization has recognized a new generic drug name for Annamycin, 'naxtarubicin,' facilitating future drug launch efforts.
Patent Protection Extended
Additional patents for Annamycin have been announced, extending protection beyond the existing composition of matter protection until at least 2040.
Promising Preliminary Data for MB-107
Preliminary numbers from the MB-107 clinical trial using Annamycin to treat advanced soft tissue sarcoma are impressive, with final data expected to draw significant attention.
WP1066 Clinical Trial Progress
WP1066, the lead STAT3 inhibitor, is in a new clinical trial at Northwestern University, showing rapid recruitment with nearly one patient per month.
Strong Market Cap and Trading Volume
Market cap has increased to over $14 million with a healthy trading volume, indicating positive investor interest.
MBRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MBRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.07 | $0.99 | -7.48% |
Mar 24, 2025 | $1.09 | $1.06 | -2.75% |
Nov 11, 2024 | $2.55 | $2.51 | -1.57% |
Aug 14, 2024 | $2.35 | $2.50 | +6.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Moleculin Biotech (MBRX) report earnings?
Moleculin Biotech (MBRX) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Moleculin Biotech (MBRX) earnings time?
Moleculin Biotech (MBRX) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MBRX EPS forecast?
MBRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.43.